Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GCT joins the ranks of other Hong Kong meme stocks like RGC, HKD, MEGL & AMTD. What's the hype?
GigaCloud Technology (GCT) is getting a major boost Friday following its initial public offering (IPO) Thursday.
That's due to meme stock investors taking notice of the fintech company.
This has shares climbing over 100% as heavy trading takes place.
GigaCloud Technology (NASDAQ:GCT) stock is continuing to rally on Friday after the Hong Kong-based fintech company launched its IPO yesterday.
That IPO saw the company list shares for $12.25 each and it included 2.94 million of them. That has the company expecting gross proceeds of $36 million from its IPO before deducting underwriter discounts.
GigaCloud Technology holding an IPO in the U.S. is somewhat surprising considering the delisting fears Chinese companies have faced. GCT isn’t worried about that though as it says it’s willing to switch auditors if need be to keep its U.S. listing.
What’s Behind the Rally of GCT Stock?
It looks like meme stock traders have latched onto GCT shares as one of their big investments. This has it joining other popular Hong Kong meme stocks, such as Regencell Bioscience, $RGC, AMTD Digital $HKD, AMTD IDEA, $AMTD and Magic Empire Global $MEGL.
$RGC was the IPO top performer for the year of 2021 with an increase of 190% (if one bought the stock on IPO and still holding).
That resulted in heavy trading yesterday as investors pumped up shares of GCT stock with its IPO. This saw shares rise as much as 62% yesterday and that momentum isn’t stopping today. As of this writing, more than 8 million shares of GCT stock have changed hands. While we don’t have a good daily average to compare that to, there’s no denying it’s a lot of momentum for the stock.
GCT stock is up 145.1% as of Friday morning.
https://investorplace.com/2022/08/gct-stock-alert-what-is-going-on-with-gigacloud-technology-today/
RGC, share float and ceo buyback.
About Regencell Bioscience (RGC)
Regencell Bioscience is an early clinical stage bioscience company using traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
Share float
Companies may decide to increase their float by issuing new shares as a way to raise capital or encourage more trading. But they may also choose to reduce their float through a stock buyback, which can result in increasing the value of shares. This usually happens if the company believes its shares have been discounted too much, wants to invest in itself, or wants to see its financial ratios go up.
CEO share buyback
CEO of RGC recently bought US$886k worth of stock. On the 25th of July, Yat-Gai Au bought around 22k shares on-market at roughly US$39.48 per share. In the last 3 months, they made an even bigger purchase worth US$1.2m. Yat-Gai has been a buyer over the last 12 months, purchasing a net total of US$2.7m worth in shares.
Until the company's market valuation reaches $1 billion, the CEO of RGC vows to assist Regencell by taking a $1 annual salary with no bonuses. Additionally, he has set aside share options for everyone but himself. He had taken the initiative in utilising more than $5.9 million of my personal assets to buy shares on the open market.
Additionally, the management group and directors have agreed to collectively extend the lock-up obligations on their stock options.
https://www.benzinga.com/news/small-cap/22/06/27852402/rgc-ceo-figuratively-putting-his-money-where-his-mouth-is
This stock is behaving like $GME. Does it also have a potential short squeeze?
The market was rocked by the short squeeze of American video game retailer GameStop Corp. in January 2021, which had serious financial repercussions for several hedge funds and resulted in significant losses for short-sellers.
The public float of the gaming retailer saw about 140% of its short positions sold. To cover those bets, there was a wild dash to buy shares, which raised the price even more.
Despite the involvement of several hedge funds, it was users of the r/wallstreetbets subreddit that in large part started the short squeeze.
The retailer's stock price reached a premarket value of more than $500 per share on January 28, 2021, when the short squeeze was at its worst. At the start of that month, the price was worth $17.25, which was almost 30 times the current price.
Regencell Bioscience Ltd. is a ticker that some investors have considered to also have the potential for a short squeeze.
With both averaging over 40% during the previous year, the short volume ratio shows a similar tendency to that of GameStop. In fact, there have been days when Regencell's shares have been shorted about 90% more than GameStop.
The CEO and founder of the Regencell possessed 10,539,159 common shares as of May 16 and recently purchased another $886,000 of RGC shares at an average price of US$39.48, increasing his shareholdings by 0.2%. He believe in the company and its future and intend to continue to put his money where his mouth is and increase shareholdings." which accounted for 81% of all issued and outstanding common shares of Regencell.
The total cumulative short volume for Regencell, as reported by a third-party data analytics provider, is over 19 million shares. However, even though there are only slightly more than 2.4 million shares outstanding after deducting the CEO and Chairman's shares, Regencell is still trading at a premium of more than 289% to its IPO price. Its total reported short volume to outstanding shares ratio (excluding the CEO and Chairman's shares ratio) is nearly twice that of GameStop, coming in at about 8 times versus just over 4 times for GameStop. Currently, GameStop is trading 50 times above its $2.52 historical low. What is the source of all the extra shares?
Retail shareholders came together as shown on Reddit and other social media platforms and forums, especially during the GameStop short squeeze, motivated by the community's desire to punish market participants who make a mistake.
https://tinyurl.com/3xhfjx6t
A sneak peak into RGC background
?? Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine.
??Regencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares.
??Majority shareholders of Regencell are insider investors.
??Regencell is comfortably poised amidst turbulent market conditions, especially for a biotech stock.
??The company has a list of successful clinical trials, with more to come in the year.
https://seekingalpha.com/article/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience
RGC Offers Stability
Its distinctive ownership structure is one of the main causes or elements that has contributed to RGC's stability. Over 81% of the company's shares are currently held by certain insiders, making them the group most likely to profit from the stock's so far favourable performance.
On the one hand, Yat-Gai Au, the company's founder and CEO, owns the majority of RGC and is its largest stakeholder with an 81% ownership. On the other hand, the remaining stockholders hold about 19% of the RGC stock.
According to the most recent data, insiders presently possess at least $333 million of the $416 million company. When examining these scenarios, investors may be led to believe that the majority of owners are corporate executives, managers, and leaders.
Although still significant, general public ownership (11.2%) and private equity ownership (7.6%) have some ability to influence business decisions about performance and expansion. However, despite being sizable enough to matter, it cannot alter company policy.
They have better control over decision-making and their course for growth because the majority of the power is vested and held within the company. Due to the fact that board members and retail investors both invest in RGC, there is a little more stability and predictability for investors wanting to make a move.
This kind of strategy has a tug-of-war quality that may make some investors a little more suspicious of the overall state of the business and its prospects for growth. Performance indicators can be measured depending on members' strategic management and goals, albeit most of their effect comes from within.
https://tinyurl.com/2yfavbwm
What Justifies RGC, At Least Right Now?
RGC is unique, and in many ways we can understand why investors have begun to take notice of the business.
The Nasdaq Biotechnology Index has only risen by 2.69% year to far, but share prices have risen by 17.03%. Share prices fluctuate between $34.79 and $35.84 on average, with some investors setting their year range closer to $59.00 per share.
The company recorded a basic diluted loss per share of $0.29 for the six months from July 2021 to December 2021, compared to a loss per share of $0.03 for the corresponding period in 2020.
The loss may have been caused by the company's unexpected rise in operational costs, which increased by about 893% from $368,465 for the six months ended December 31, 2020, to $3,658,906 for the same period in 2021.
In comparison to $0.06 million in June 2021, the company declared cash available of $19 million in December 2021. The primary source of funds was the net proceeds of the company's IPO, which also included earnings from the selling of approximately 22.7 million extra shares.
When the company first went public in July 2021, share prices were far lower than they are now. A month later, in August 2021, share prices experienced a surge of up to 204% within a single trading session. Since becoming public, Regencell has successfully treated more than 88 COVID patients, with a 94% success rate in removing symptoms within 6 days. They also have continuing clinical investigations for ADHD/ASD, and they were added to the MSCI world microcap index. Additionally, RGC was among the Nasdaq's top-performing stocks in 2021, according to www.stockanalysis.com.
Regencell began conducting early trials for ADHD/ASD in late 2017. The stock was trading in the low $20 level at the time. Share prices increased to above $40 by mid-February 2022 before declining to the $20 area.
RGC has done admirably since April 2022, with share prices swinging above $30, despite choppy market conditions and unfavourable investor sentiment. Positive clinical outcomes pertaining to the RGC-COV19 TCM formula developed by the business are what have helped the stock performance recover.
In our opinion, when the business announces a second clinical examination of a standardised TCM formulation for the treatment of ADHD and ASD, RGC will see another price fluctuation. In order to provide an industry standard for therapy, dosage, side effects, and gauging patient response, Regencell has been working on this.
Investor interest has been maintained by RGC's steady performance and encouraging track record, which has remained largely unchanged. RGC may outperform weak market conditions for investors who can more easily handle tiny purchases.
https://seekingalpha.com/article/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience
Humble beginnings lead to human ingenuity.
Yat-Gai Au founded Regencell Bioscience so that more people can benefit from natural and holistic treatments with a goal to provide everyone equal access to such treatment for many years to come.
Throughout the last few years, several people have largely contributed to the overall success of RGC. James Chung (Chief Operating Officer) and Dr. Chao (Chief Medical Officer), who joined Regencell in 2015 and 2019, respectively, were inspired by their personal experience with TCM and the major improvements they saw on ADHD and ASD patients.
"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.
The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"
In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
CEO spent millions of his personal finances on purchasing company shares.
Since the company went public, Yat-Gai, the CEO of Regencell Bioscience $RGC, has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment.
"Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.
To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.
"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."
Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.
"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."
The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Stocks with low float that have growth potential.
A low float stock is a stock with a relatively small number of available shares on the market.
For example, a company could have 50 million total shares but only 10% available for the public markets. This means traders only have access to five million shares.
That doesn’t mean these companies don’t have a lot of shares. They often do. But they’re usually closely held by institutional investors, employees, or other major stakeholders. When that volume and catalysts kicks in though, it can offer some great trading opportunities.
Stocks with low float:
1) AMCON Distributing Company (NYSEAMERICAN: DIT)
DIT has a float of approximately 152,000 shares.
2) Biglari Holdings Inc. (NYSE: BH)
BH has a float of 913,000 shares.
3) Chicago Rivet & Machine Co. (NYSEAMERICAN: CVR)
CVR has a float of 786,000 shares.
4) Regencell Bioscience (NASDAQ: RGC)
RGC has a float of 1.41 million shares
5) Wah Fu Education Group Limited (NASDAQ: WAFU)
WAFU has a float of 1.18 million shares.
6) Euro Tech Holdings Company Limited (NASDAQ: CLWT)
CLWT has a float of 1.37 million shares.
7) Regional Health Properties Inc. (NYSEAMERICAN: RHE)
RHE has a float of 1.62 million shares.
https://stockstotrade.com/low-float-stocks/
A short squeeze on $GME created a return of 51x (current price to its historical low) to 191x (historical high to its historical low), what is the potential for $RGC if there is a short squeeze? https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
To add to watchlist = $RGC
1) $RGC has a defined mission to assist people improve their lives.
2) It has a low public float of 1.4 million shares, which are held 89% by insiders who have no plans to sell.
3) Possibility of a short squeeze.
4) A HK company (comparable to $HKD and $MEGL, with the exception that $HKD and $MEGL lack any strong foundations).
5) Strong investor backup by Samuel Chen, a significant backer of RGC and a successful early investor in Zoom Video Communications (NASDAQ: ZM).
More about the CEO and the company’s core values and get in early: https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
RGC- Growth-oriented company with a clear vision to help people improve their lives.
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.
The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"
In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
Should Investors Follow Insiders When They Buy?
Reasons to Follow Insider Trading
The argument for shadowing insiders makes a lot of sense. Executives and directors have the most up-to-date information on their companies' prospects. Intimately acquainted with cyclical trends, order flow, supply and production bottlenecks, costs, and other key ingredients of business success, these insiders are way ahead of analysts and portfolio managers, not to mention individual investors. Insiders' decisions (legal or not) to trade in their own companies' stocks are certainly worth examining.
When company insiders start buying shares of the company, it may be a signal for outside investors to follow suit, but looking at which insiders are acting matters.
One of the greatest investors of all time, Peter Lynch, was noted as saying that "insiders might sell their shares for any number of reasons, but they buy them for only one reason: they think the price will rise."
Information of insider activity can be found for free on several financial websites.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
• Chairman and CEO support. Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au.
? Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
? Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
? Will not award share options for himself;
? Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
• Billionaire investor backing. Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.
• Stock option lock-up extended. All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
• Royalties. Under the agreement with their strategic partner and TCM practitioner, Mr. Sik-Kee Au, creator of the original TCM formulae that form the basis of RGC’s intellectual property, RGC will pay 3% of net revenue, which will in turn be donated to charitable institutions/trusts at the choice of the TCM Practitioner.
https://www.investopedia.com/articles/02/121002.asp
https://www.investopedia.com/articles/02/121002.asp
https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html
In RGC chart, there are six significant support areas that we can observe.
A support area between 32.87 and 33.21. A combination of many trend lines in various time frames creates this zone.
A support area between 31.99 and 32.15. Multiple trend lines and significant moving averages in various time frames combine to form this zone.
A trend line in the daily time frame provides support at $30.23.
a support area between 28.98 and 29.25.
A trend line in the daily time frame provides support at 26.25.
Support in the daily time frame comes from a horizontal line @20.84.
When examining the resistance, one crucial area stands up. A resistance zone between 34.01 and 34.26. Multiple trend lines and significant moving averages in the daily time frame combine to form this zone.
Video Interview with the team from Regencell Bioscience Holdings Limited (RGC).
SNN Live spoke with the team from RGC, including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director, via Zoom to discuss.
Possible Short Squeeze in $rgc
Stocks with high short interest are often very volatile and are well known for making explosive upside moves (known as a short squeeze). Stock traders will often flock to such stocks for no reason other than the fact that they have a high short interest and the price can potentially move up very quickly as traders with open short positions move to cover.
"The possibility of a short squeeze is one reason some analysts look at a high amount of short interest as a bullish indicator. Short Interest is the fuel, performance is the fuse, says ShortSqueeze.com"
- USA Today
Both $RGC and $GME's short volume ratios, which have averaged over 40% over the past year, follow a similar pattern. In fact, there have been days when Regencell's shares have been shorted about 90% more than GameStop. It should be noted that, in comparison to GME, RGC has a very low float.
If two companies both have 25% short float, but one has 10M unshorted shares floating and the other has 200M unshorted shares floating, the first one is clearly more susceptible to a short squeeze. The effect of this change is that the updated model will favor low-float companies over others, all other things being equal.
Little shares of $RGC are also available for shorting, but it appears that more shares have been sold short than are currently available.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price. Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52. Where are all the extra shares coming from?
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
https://fintel.io/shortSqueeze
HighShortInterest.com
Current $RGC Borrow Fee
At 2022-08-09 10:30:04, there were 2,000 shares available with a fee of 130.9980%.
Highest borrowing fee ever in $rgc's history
https://chartexchange.com/symbol/nasdaq-rgc/borrow-fee/
Why should you invest in small-market-cap stocks?
Small cap stocks have the potential to maximize returns. The best reason to invest in small cap stocks is their greater potential to deliver outsized returns compared to larger companies. For instance, it's considerably easier for a $1 billion company to become a $10 billion one than it is for a $100 billion company to grow to $1 trillion. In fact, some of the biggest companies in the world once traded in the small cap range, such as Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX). If you had bought and held these stocks when they were small, you would have seen your initial investment appreciate more than 100 times.
Small cap stocks tend to have higher growth rates. Again, it's easier for a smaller company to double its revenue; mature companies tend to see slowing revenue growth.
Small cap stocks are shares of publicly traded company with market values between $300 million and $2 billion. Some companies in the small cap universe (or in small cap indexes) may at any given time have market caps substantially higher than this range because the share prices of these businesses can be extremely volatile.
The printing and imaging company Eastman Kodak Co., the retail pharmacy chain Rite Aid Corp., and the insurance company Genworth Financial Inc. are some of the companies whose stocks are categorised as small caps.
Another company with a small cap is $rgc, Regencell Bioscience with 433 million market cap. The company has gained 232% gain since IPO (July 2021). RGC'S CEO personally funded the company and did not pay himself back after IPO. The CEO has also continuously funded the company since its incorporation up to the IPO without bank borrowing. He converted his shareholders’ loan of $3.25 million to RGC’s ordinary shares upon listing. More uniquely, the CEO also promised not to withdraw salary and bonus of more than US$1 until the company reaches US$1 billion market capitalisation.
https://www.investopedia.com/investing/top-small-cap-stocks/
https://www.fool.com/investing/stock-market/types-of-stocks/small-cap-stocks/when-to-buy/#:~:text=The%20best%20reason%20to%20invest,to%20grow%20to%20%241%20trillion
https://finance.yahoo.com/quote/RGC?ltr=1
Similarities between the top-performing IPOs in 2021 and 2022.
According to stockanalysis.com/ipos/2021/, Regencell Bioscience ($RGC) is now the best-performing stock of all 2021 IPOs. RGC is still rated first as of August 1, 2022, having gained 237 percent more than its $9.50 IPO price.
A recently traded stock that has skyrocketed after its mid-July 2022 AMTD Digital $HKD debut (as of August 3, 2022)
The controlling shareholder, AMTD Group Company Limited, was founded by billionaire Li Ka-shing’s CK Hutchison Holdings Limited in 2003. The IPO price of HKD was $7.80, and it closed at $742.00 on August 1, 2022, a rise of over 9,000 percent. The leading company at the moment is Regencell Bioscience, $RGC. Despite RGC leading all 2021 IPOs in performance, HKD is currently outperforming RGC.
Due to HKD's rapid growth, which has resulted in an astonishing 90 times bagger in a short period of time, the company has attracted a lot of short positions.
For HKD, the major shareholder has approximately 88.7 percent of the shares, whereas RGC major shareholders holds approximately 81.2 percent. The float of both businesses is small.
https://www.benzinga.com/general/biotech/22/08/28316977/a-look-into-the-top-performing-ipo-stock-of-2021
The CEO of RGC promised to live up to his words.
RGC has adopted a more open strategy that is in line with shareholders' long-term interests, in contrast to some early-stage companies where it can be challenging to sort through the numerous ways that founders and executives may benefit whether or not the company succeeds.
The CEO will continue to receive a $1 annual salary with no bonus until Regencell reaches a $1 billion market valuation in order to assist the company even further. Additionally, he has reserved share options for every employee but himself. Additionally, he has taken the initiative to use more than $5.9 million of his own money to buy shares on the open market. Not to mention, the RGC management team and directors have collectively extended their lock-up commitments on their stock options. The CEO hopes that these actions demonstrate their dedication to and faith in the business.
Thanks for your support! pic.twitter.com/OEL7M8a4y9
— Yat-Gai Au (@yat_gai) July 27, 2022
Recent information and impending catalysts for $RGC
RGC launched a follow-up research for their experimental liquid formula RGC-COV19TM in the treatment of COVID-19 symptoms on May 18, 2022. (EARTH-B Trial). The second study expanded on the encouraging findings from the initial EARTH experiment (EARTH-A Trial), which was carried out in 2020–2021. In the two studies, 95.5 percent of the participants (n=81) reported complete symptom relief six days after therapy, with the exception of occasional coughing and loss or reduction in sensation of taste and/or smell (sensory dysfunction).
RGC anticipates publishing data from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.
In order to set standards for therapy, dosing, adverse effects (AEs), and assessing patient response in a methodical and reproducible manner, Regencell Bioscience's initial clinical study was created. Seven adolescents with clinically confirmed ASD or ADHD, ranging in age from five to eleven, participated in the 2018–2019 study. Subjects got a personalised TCM formula for up to three months after stopping all current treatments and medications. Parental interviews and four validated assessment tools, such as the Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS), and Pelham (SNAP)-IV 26-item Parent Rating Scale, were used to gauge the responses of the patients (SNAP-IV-26). During the course of treatment, all seven patients showed a reduction in symptoms on all four scales.
The second clinical trial assesses how three standardised TCM formula mixes (for mild, moderate, and severe impairment) respond to children in the same age group. Weekly practitioner meetings, twice daily medication for three to twelve months, and monthly assessments are all part of the study's design. The outcomes will be used to submit a proprietary Chinese medicine (pCm) registration application in Hong Kong, making the product available for purchase both over the counter and in other clinic.
To support its findings, Regencell is concentrating on its clinical research. Through these initiatives, the infrastructure for manufacturing and the supply chain that is needed to obtain pCm registration will be built. The commercialization of Regencell Bioscience's standardised formulations and pCm registration in Hong Kong are both subject to a four-year timeline. A lot of tasks lie ahead for the company:
•Finishing its second clinical trial and reviewing outcomes.
• Running more clinical studies to support the use of its patented formulas for ASD/ADHD and other uses.
• Getting IP protection in Hong Kong and other markets through the acquisition of patents and other types of IP.
• Setting up a manufacturing infrastructure and supply chain that complies with registration criteria.
• Compiling and filing paperwork for pCm approval.
• Develop the infrastructure and marketing and distribution plan.
We are encouraged by RGC's thoughtful, methodical approach to developing its therapies and communicating its progress to shareholders, which we believe may be a sign of greater things to come as it moves towards commercialization. RGC's steady share price ascent in recent weeks.
• Completing its second clinical trial and evaluating results.
• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
• Obtaining patents and other forms of IP protection in Hong Kong and other markets.
• Establishing manufacturing capability and supply chain that will meet registration requirements.
• Assembling and filing documentation for pCm approval.
• Build out its marketing and distribution strategy and infrastructure.
•
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.
https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html
Performing IPO 2021
Within a few months or years following their initial public offering, the largest stock market winners often experience significant price increases (IPO). Therefore, it is beneficial to identify and keep tabs on businesses that are either recently or soon to be going public.
In 2021, the US stock market saw an all-time high of 1035 initial public offerings. It was also a record, that it was 120.4% higher than the 480 IPOs in 2020.
RGC has gained around 236%, currently priced at $31.97, from the IPO price of $9.50.
https://stockanalysis.com/ipos/2021/
$RGC quick chart analysis
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Watching this as it chops around still rising 40 weekly small moving average on light volume. Accumulation day on Friday 07/29. Seeing 89.1% insider owned, little to no shares short.
Yat-Gai Au has increased his stake in Regencell Bioscience Holdings Limited.
Those who keep track of Regencell Bioscience Holdings Limited (NASDAQ:RGC) will undoubtedly find it interesting that Yat-Gai Au, the company's founder, recently bought shares for a whopping US$886k at an average price of US$39.48. Even though it just slightly increased their holding size, it is still a significant change by our standards.
Insider Transactions During The Past Year Associated With Regencell Bioscience Holdings.
Notably, Founder Yat-Gai Au has acquired Regencell Bioscience Holdings shares on several occasions this year besides the most recent one. They purchased US$1.2m worth of shares earlier this year for US$25.23 each. We still believe that insider buying is a good thing, despite the fact that the transaction was done at a price that was much lower than the most current price (US$31.32). It does not provide much insight into whether insiders could find the current pricing alluring because it took place at a lesser valuation.
Over the past 12 months, Yat-Gai Au purchased 90.78k shares at an average cost of US$29.35. The graph below displays insider transactions over the previous year for both businesses and people. Click on the graph below to find out exactly who sold, for how much, and when.
RGC Insider Trading Volume July 28th 2022
There are always plenty of stocks that insiders are buying
Regencell Bioscience Holdings Is Owned by Insiders.
In order to better understand how closely associated a company is with insiders, I like to look at how many shares insiders possess in that company. Leadership in a corporation is frequently more aware of shareholder interests when insider ownership is high. It's fantastic to see that insiders at Regencell Bioscience Holdings hold 81 percent of the company, which is valued at roughly US$330 million. This amount of insider ownership is something I prefer to see since it makes management more likely to consider the interests of shareholders first.
https://www.nasdaq.com/articles/yat-gai-au-is-the-founder-of-regencell-bioscience-holdings-limited-nasdaq%3Argc-and-just
Founder recently bought US$886k worth of stock.
On the 25th of July, Yat-Gai Au bought around 22k shares on-market at roughly US$39.48 per share. In the last 3 months, they made an even bigger purchase worth US$1.2m. Yat-Gai has been a buyer over the last 12 months, purchasing a net total of US$2.7m worth in shares.
Until the company's market valuation reaches $1 billion, the CEO of RGC vows to assist Regencell by taking a $1 annual salary with no bonuses. Additionally, he has set aside share options for everyone but himself. He had taken the initiative in utilising more than $5.9 million of my personal assets to buy shares on the open market.
Additionally, the management group and directors have agreed to collectively extend the lock-up obligations on their stock options.
About Regencell Bioscience:
The development, investigation, and promotion of TCM for the management of neurocognitive diseases and degeneration, such as attention deficit hyperactivity disorder and autism spectrum disorder, are its primary foci.
Thanks for your support! pic.twitter.com/OEL7M8a4y9
— Yat-Gai Au (@yat_gai) July 27, 2022
Sector rebalancing and nine stocks to keep an eye on amid a downturn.
The commonly accepted definition of a recession is a brief period of decreased commerce and manufacturing activity that is typically indicated by a dip in GDP over two consecutive quarters. The GDP shrank at an annual pace of 1.4 percent, down from 6.9 percent in the fourth quarter of 2021, according to the Bureau of Economic Analysis.
Although the macro picture is at best gloomy, it is important to comprehend the larger market dynamics that show where money is moving, such as the economic cycle and sector rotation.
A recession is a well-known natural component of an expanding economy and a stage of the economic cycle. The economy's transition from a growth stage to a recession and back to growth is known as the economic cycle. Since it directly affects stock prices in relation to corporate profitability, this is perhaps the factor with the most impact on the overall markets.
The numerous market sectors, each of which is responsive to a distinct stage of the cycle, are what link the stock market to the economic cycle.
Are you still perplexed? This ought should make it simple.
When the economy is expanding, some industries (such as real estate, consumer brands, and consumer goods) will perform better than others (Healthcare, Food, Consumer Staples, Utilities)
This is referred to as sector rotation or the movement of capital by investors throughout the course of the economic cycle.
Investors typically shift into less cycle-sensitive sectors, such consumer staples and utilities, when the economy is headed for a recession. These sectors are referred to as defensive sectors because they can provide a certain level of protection during a recession.
Some of those defensive names include:
1) Coca-Cola Co
2) Albertsons Companies Inc
3) Altria Group Inc
4) NRG Energy Inc
5) PG&E Corporation
6) Clearway Energy Inc
7) National HealthCare Corporation
8) HealthStream, Inc
9) Regencell Bioscience Holdings Ltd
On the other hand, after a recession ends, investors switch to stocks with a high cycle sensitivity, including industrials and consumer cyclicals.
https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI
RGC CEO promises to continue to support Regencell by drawing a $1 annual salary with no bonus until the company's market capitalization reaches $1 billion.He has also reserved share options for all employees except for himself. He had taken the lead in purchasing shares from the open market using over $5.9 million of my personal funds.
The management team and directors have also made a collective extension of lock-up undertakings on their stock options. These efforts portrayed commitment and confidence in the company.
Thanks for your support! pic.twitter.com/OEL7M8a4y9
— Yat-Gai Au (@yat_gai) July 27, 2022
Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders own more than half of Regencell Bioscience Holdings Limited. This gives them effective control of the company. So they have a US$430m stake in this US$531m business. It is good to see this level of investment.
Regencell Bioscience Holdings
RGC
Share Price 7 Day 1 Year
31.32 -13.0% 243.8%
Founder recently bought US$886k worth of stock
On the 25th of July, Yat-Gai Au bought around 22k shares on-market at roughly US$39.48 per share. In the last 3 months, they made an even bigger purchase worth US$1.2m. Yat-Gai has been a buyer over the last 12 months, purchasing a net total of US$2.7m worth in shares.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings#information
Regencell Bioscience Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
Regencell began its investigational approach towards COVID-19 treatment when a friend of Regencell contracted COVID-19 in March 2020. To treat his friend, the TCM Practitioner used his proprietary TCM formula which he has been using over the past 30 years to treat various cold and flu patients, including during the 2003 SARS outbreak. The TCM Practitioner subsequently treated 9 voluntary COVID-19 patients in the United States using the proprietary TCM formula.
Study results showed that the treatment was effective. As Regencell has a mission to save lives, improve patients’ well-being and address unmet needs in the market, Regencell aims to make its natural and holistic treatment available to everyone in need.
From March 2020 to August 2021, Regencell set up protocols and procedures to conduct the EARTH efficacy trial in Malaysia and the United States.
RGC-COV19TM is designed to reduce COVID-19 symptoms such as fever, fatigue, cough, sore throat, runny nose, headache, nausea, chills, drowsiness, shortness of breath, persistent chest pain and muscle ache as the medicine works to (i) reduce and clear the mucus and phlegm from the upper respiratory system; (ii) dispel exterior viral pathogen via heavy sweats, urine and excrement; (iii) clear endogenous and liver heat; (iv) detox the liver; and (v) improve body circulation. By applying the TCM Practitioner’s “Sik-Kee Au TCM Brain Theory®”, RGC-COV19TM is also designed to remove blood clots from the brain and restore the patient's brain functions.
RGC-COV19TM (RGCA-CV01) is administered at 1 dose of RGCA-CV01-1Na (approximately 230ml) and 1 dose of RGCA-CV01-2Da (approximately 230ml) each time, with 1 dose of RGCA-CV01-1Na to be taken starting from the night of the first day of treatment and 1 dose of RGCA-CV01-2Da to be taken after lunch the next day, until symptoms are eliminated.
About RGC-COV19TM
RGC-COV19TM (RGCA-CV01) is an investigational, natural, orally administered liquid formula which aims to reduce and eliminate COVID-19 symptoms.
RGC-COV19TM is a natural formula designed by the TCM Practitioner according to the TCM Practitioner’s brain theory known as “Sik-Kee Au TCM Brain Theory®” and can be taken safely for two to three weeks. In conducting EARTH, the treatment was limited to 6 days in order to evaluate its efficacy in reducing and eliminating COVID-19 symptoms. The “TCM Practitioner” refers to our strategic TCM research partner, Sik-Kee Au, father of our founder and Chief Executive Officer.
According to the brain theory, brain functions depend on the oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart’s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response.
RGC-COV19TM is designed to strengthen the heart’s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions. Regardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage by setting off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which in turn suppress brain functions. RGC-COV19TM is formulated to generate more responsive cognitive functions which in turn stimulate the body’s own healing mechanism.
Original article:
https://www.businesswire.com/news/home/20220518005682/en/
27 Recession-Resistant Stocks To Look At Now
When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not exist.
On the other hand, recession-resistant companies are what a savvy investor searches for during the absence of a bull market, as we are now.
Historically, cyclical sectors such as financial and consumer directories have outperformed during bull markets. These equities are frequently susceptible to interest rates and economic growth, so they perform worse than others during a bear market or imminent recession.
Consumer preferences shift from optional and luxury purchases to essential home products and services during a recession as individuals are more concerned with their bottom line.
During uncertain periods such as this, the smart money rotates into recession-resistant or defensive sectors like Consumer Staples, Utilities and Health Care, all of which historically perform well during a recession.
Energy (+49.17%) is the sector with the most significant returns this year, owing to rising oil prices, supply-chain concerns, and demand for gas, energy equipment, and services while the war in Ukraine continues.
This bear market is different. Year-to-date, the returns for the following sectors are:
Consumer Staples: -0.62%
Utilities: +0.73%
Health Care: -8.1%
On the surface, these sectors could look like uncertain investments, bur peeking into them tells a different story and provides investment ideas.
Consumer Staples:
Beverages: +2.21%
Coca-Cola Co (NYSE: KO)
PepsiCo, Inc. (NASDAQ: PEP)
Constellation Brands, Inc (NYSE: STZ)
Food Products: +8.76%
Albertsons Companies Inc (NYSE: ACI)
SpartanNash Co (NASDAQ: SPTN)
Andersons Inc (NASDAQ: ANDE)
Tobacco: +9.27
Altria Group Inc (NYSE: MO)
British American Tobacco PLC (NYSE: BTI)
Vector Group Ltd. (NYSE: VGR)
Utilities:
Electric Utilities: -1.71%
NRG Energy Inc (NYSE: NRG)
DTE Energy Co (NYSE: DTE)
OGE Energy Corp. (NYSE: OGE)
Multi-Utilities: +9.05%
PG&E Corporation (NYSE: PCG)
Black Hills Corp (NYSE: BKH)
Exelon Corporation (NASDAQ: EXC)
Independent Power and Renewable Energy: -13.83%
Clearway Energy Inc Class A (NYSE: CWEN.A)
NextEra Energy Inc (NYSE: NEE)
First Solar, Inc. (NASDAQ: FSLR)
Health Care:
Providers & Services: +1.23%
National HealthCare Corporation (NYSE: NHC)
Davita Inc (NYSE: DVA)
Alignment Healthcare Inc (NASDAQ: ALHC)
Health Care Tech: +1.22%
Sophia Genetics SA (NASDAQ: SOPH)
Computer Programs & Systems, Inc. (NASDAQ: CPSI)
HealthStream, Inc. (NASDAQ: HSTM)
Pharmaceuticals: -0.55%
Viatris Inc (NASDAQ: VTRS)
Regencell Bioscience Holdings Ltd (NASDAQ: RGC)
Prestige Consumer Healthcare Inc (NYSE: PBH)
Original link:
https://www.benzinga.com/news/small-cap/22/05/27083377/27-recession-resistant-stocks-to-hold-through-tough-times
$RGC Short Squeeze?
The stock of Regencell Bioscience Limited (NASDAQ:RGC) has untapped potential for a short squeeze. The pattern of the short volume ratio is similar to that of GameStop Corp. (NYSE:GME), with both ratios averaging above 40% throughout the previous year. In fact, RGC has more short positions than GME, with some days seeing short positions of almost 90%.
https://www.valuewalk.com/game-stop-or-game-on-rgc -has-it-all-and-twice-more/
RGC Technical Analysis
Taking everything into account, RGC scores 7 out of 10 in our technical rating. RGC was one of the better performers in the overall market, it is still ok in the medium term time frame.
Looking at the yearly performance, RGC did better than 99% of all other stocks. We also observe that the gains produced by RGC over the past year are nicely spread over this period.
RGC is part of the Pharmaceuticals industry. There are 264 other stocks in this industry. RGC outperforms 99% of them.
The short term trend is negative, but the long term trend is still positive. So although the long term is still positive, this may be a trend turning. Do your due diligence.
RGC is currently trading in the middle of its 52 week range. The S&P500 Index is currently trading in the lower part of its 52 week range, so RGC is still doing slightly better than the market.
https://www.chartmill.com/stock/quote/RGC/technical-analysis
Why would a CEO buy shares in their company?
A Chief Executive might buy shares in their own company even though the market has the stock price falling for any number of reasons, but two of the commonest reasons are:
First, they see the stock as cheap. As CEO they know what is going to happen to the company in the next few weeks. Their inside knowledge about the companies prospects can be used to purchase a stock which has gone on sale. As long as the purchase is properly declared and noted they can buy the stock for their own portfolio.
The second reason may be to show the market that the company stock is being undervalued by the market. A CEO buying stock with their own cash is a strong sign that the company is doing well and that the market is wrong about prospects. Some companies even contract their senior officers to purchase a quantity of shares in the company in order to consider their various actions on the board of management more carefully. As stock holders in the company they hope that a CEO will be more thoughtful of the value of the stock than someone who has no interest due to their lack of skin in the game.
For some early-stage companies, it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, however, Regencell Bioscience, RGC ($rgc), has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Since RGC’s incorporation in October 2014 up to the IPO, the company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au.
Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50. He pledged not to draw salary and bonus of more than USD $1 until the company reaches USD $1 billion market capitalization. He also will not award share options for himself.
Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
https://www.forbes.com/advisor/investing/stock-buyback/#:~:text=A%20stock%20buyback%20is%20when,fund%20operations%20and%20other%20investments
https://www.quora.com/Why-would-a-CEO-buy-shares-in-their-company-when-the-company-stock-is-selling-off/answer/William-Elliott-29?ch=10&oid=336350002&share=85576911&srid=hIzcnI&target_type=answer
https://newsfilter.io/articles/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo-3b36a9b6af854a3aa5240d3148ccbd80
Biotech stocks could be a big opportunity for exponential gains.
Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early-phase trials of things like novel drugs, a positive result at any phase can end up producing a favourable reaction in the stock market. And for biotech stock investors, this could be a big opportunity for exponential gains.
Regencell Bioscience is an early-clinical bioscience company that focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases that affect the immune system, such as COVID-19.
The company has been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families, and caregivers and to become a market leader for the treatment of these disorders. rGC aims to achieve improvements in both symptoms and overall health of patients as compared to currently available medications on the market. They are passionate about transforming the lives of patients, their families and caregivers and helping them feel their best physically, mentally, and emotionally.
Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund the second research study (currently ongoing), TCM formula and products, staff salaries, product and intellectual property registrations, facilities rental, renovations, and equipment, for working capital and other general corporate purposes.
The company launches three liquid based standardized TCM formula candidates for mild, moderate and severe ADHD and ASD patients. The company made a stellar performance after its IPO and gained 223% since then.
After hitting a six-year low in mid-June, biotech stocks seem to have regained their footing. Let's take a look at the top biotech stock to date.
Top Biotech Stock 2022
1) Amphastar Pharmaceuticals (AMPH)
Amphastar is the No. 1 biotech stock, leading an industry group of nearly 900 companies. Its biggest product is Primatene Mist, an over-the-counter asthma inhaler that temporarily relieves mild symptoms of intermittent asthma. In the first quarter, the inhaler brought in nearly $24.7 million in sales, growing 34% year over year.
2) Dynavax Technologies (DVAX)
Dynavax is a vaccine company. It makes a hepatitis B vaccine for adults called Heplisav-B. The company also makes a second vaccine that adds an adjuvant to Heplisav-B. Adjuvants are substances that boost the immune response of a vaccine.
Last quarter, the two products brought in $114 million in sales, surging 37% year over year. That was below more bullish views for $154.3 million, however, and the biotech stock toppled 6% on the report.
3) Vertex Pharmaceuticals (VRTX)
Vertex is one of the biggest biotech stocks in terms of market cap. It is also a Tech Leader. The company is the de facto leader of the cystic fibrosis drug market. Now it's expanding into other efforts. Vertex is partnered with Crispr Therapeutics (CRSP) on a gene-editing approach to a pair of blood diseases. Further, Vertex recently announced its $320 million plan to buy its partner in diabetes treatment, privately held ViaCyte. The companies are testing a cell replacement drug in type 1 diabetes.
4) Alkermes (ALKS)
Alkermes works in the neuropsychiatric segment. The company sells Vivitrol, a treatment for alcohol or drug dependence, and Aristada, a schizophrenia treatment. Its newest drug is Lybalvi, a treatment for bipolar 1 disorder and schizophrenia. The company aims to improve on older medicines with unwanted side effects. Lybalvi, for example, uses an older antipsychotic that causes weight gain. A second drug mitigates that side effect.
5) Corcept Therapeutics (CORT)
Biotech stock Corcept is gaining steam following the reversal of Roe v. Wade.
The company sells commercial treatment Korlym. Korlym treats Cushing's syndrome, a disorder in which the body makes too much of the hormone cortisol. That can lead to weight gain, a hump between the shoulders, easy bruising and weak muscles. The biotech stock recently broke out of a cup base with an entry at 25.78. Shares are now beyond the 5% chase zone. Corcept stock also has matching Composite and Relative Strength ratings of 98.
Another biotech stock worth monitoring for:
6) Regencell Bioscience Holdings (RGC)
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. The company made a stellar performance after its IPO and gained 223% since then.
https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/
Regencell Bioscience Holdings ($rgc) has gained approximately 223% since its IPO. It went public on the Nasdaq Capital Market on July 16, 2021, in a traditional IPO process.
The company received $21.9 million in gross proceeds from the offering, which is expected to be used to fund the second research study, the company’s TCM formula and products, and general corporate purposes.
On July 20, RGC announced the closing of its public offering at $9.50 per share. The current share price as of 17 July 2022 (a year after its IPO listing) is at $37.30. RGC is a Traditional Chinese Medicine (TCM) biosciences company headquartered in Causeway Bay, Hong Kong. The company conducts research, develops, and commercialises TCM to treat degeneration and neuro-cognitive disorders.
https://pennystocks.com/featured/2021/08/20/rgc-stock-rallying-mistaken-identity-penny-stocks/?amp
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Long Covid Treatments: Up To 23 Million
Axcella, Ampio, Regencell and Tonix include long Covid treatments in their pipelines. First Wave is working on gastrointestinal side effects of Covid-19. Aim is testing out a treatment for Covid-19 patients with cancer. Humanetics is looking at lung injuries in Covid-19 patients.
The U.S. Government Accountability Office estimates up to 23 million people in the U.S. have long Covid. Research is still in its infancy, though. Not every Covid-19 case is diagnosed. Further, symptoms of long Covid vary and manifest themselves differently in each person.
The phenomenon isn't new. Survivors of the original SARS virus have reported chronic fatigue four years after the initial infection. The GAO estimates the post-Covid condition could push 1 million Americans out of the workforce, highlighting the need for long Covid treatments.
https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/
Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period.
Regencell Bioscience Holdings Limited announced the results from an analysis of a total of 51 individuals enrolled in its additional Evaluation and Assessment of RGC-COV19TMTCM through a Holistic approach efficacy trial conducted by Regencell Bioscience Asia Limited of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation).
These results are consistent with the earlier analysis announced in February 2022, showing RGC-COV19TM is effective in reducing and eliminating COVID-19 symptoms within 6 days, which in turn reduces the risk of hospitalization and death. The results have yet to be peer-reviewed.
While emerging new COVID-19 variants continue to remain a threat to the public health, Regencell will continue to work in tandem with its R&D units to develop new breakthroughs designed to transform the way COVID-19 is being managed globally and provide safe and effective treatment for everyone.
RGC Short Interest Compared To GameStop?
The short squeeze of American video game retailer GameStop Corp $GME in January 2021 took the market by storm, causing major financial consequences for some hedge funds and large losses for short-sellers.
Roughly 140% of the game retailer’s public float had been sold short. There was a mad rush to buy shares to cover those positions, which caused the price to rise further.
Although a number of hedge funds participated, the short squeeze was largely triggered by users of the subreddit r/wallstreetbets.
At the height of that episode, on January 28, 2021, the short squeeze caused the retailer’s stock price to reach a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of that month.
One ticker that some traders have looked at to also have short squeeze potential is Regencell Bioscience Ltd, $RGC
The short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year. In fact, Regencell has sometimes been more heavily shorted than GameStop, with occasional days close to 90% shorted.
Although Regencell and GameStop stocks’ short volume profiles might be considered to be similar, not as much is known about Regencell. As of May 16, the company’s founder and CEO held 10,539,159 ordinary shares, representing 81% of the total number of issued and outstanding ordinary shares in Regencell.
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
CEO of Regencell Bioscience $RGC, pledged to not draw salary and bonus of more than USD $1 until the company reaches USD $1 billion market capitalization.
• Billionaire investor backing. Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.
• Stock option lock-up extended. All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
• Royalties. Under the agreement with their strategic partner and TCM practitioner, Mr. Sik-Kee Au, creator of the original TCM formulae that form the basis of RGC’s intellectual property, RGC will pay 3% of net revenue, which will in turn be donated to charitable institutions/trusts at the choice of the TCM Practitioner.
https://stockhouse.com/companies/bullboard?symbol=rgc&postid=34808883